Metabolic screening of tumors could become important, when specific therapies for metabolically dysregulated cancers with SDHx, FH, or IDH1/2 PV become available, as targeted LC-MS/MS analysis is faster and cheaper than sequencing analyses. Here, FH is linked to cancer.